2004
Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy
Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 2004, 25: 94-102. PMID: 14698135, DOI: 10.1016/j.cyto.2003.10.004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsAnxietyBloodBreast NeoplasmsCyclophosphamideCytokinesData Interpretation, StatisticalDoxorubicinFatigueFemaleFluorouracilHumansInterleukin-1Interleukin-10Interleukin-12Interleukin-6Interleukin-8Middle AgedNauseaPaclitaxelPainPatient SelectionQuality of LifeTumor Necrosis Factor-alphaConceptsFlu-like symptomsIL-10 levelsIL-6IL-8IL-10Paclitaxel groupHealthy volunteersPaclitaxel chemotherapyJoint painIL-12Inflammatory cytokinesPlasma levelsTNF-alphaDay 3Single-agent paclitaxelBaseline cytokine levelsIL-8 levelsTransient side effectsHigh-dose treatmentWeekly paclitaxelCytokine levelsFAC chemotherapyMusculoskeletal symptomsCancer patientsIL-1beta
2000
Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors.
Madden T, Tran H, Beck D, Huie R, Newman R, Pusztai L, Wright J, Abbruzzese J. Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Clinical Cancer Research 2000, 6: 1293-301. PMID: 10778954.Peer-Reviewed Original ResearchConceptsConcentration-time curveDose levelsPhase IMajor nonhematological toxicityAntitumor activityAdvanced solid tumorsDose-limiting toxicityPlasma concentration-time dataEpisodes of thrombocytopeniaRapid distribution phaseParent drug concentrationsConcentration-time dataPercentage of declineVivo tumor modelsNonhematological toxicitiesObjective responseTwo-compartment modelSevere anemiaClinical PharmacokineticsCytokine supportPlasma levelsIntrapatient variabilityClinical dataNovel agentsPharmacodynamic studies